Research and Development of Drugs In Silico through Protein and Bioprotein Engineering/De Novo Design.
DesignInSilico, in its own pipeline, strategically focuses on and specializes in the research, creation, engineering and design of PROTEINS, BIOPROTEINS, and PEPTIDES (proteins with large amino acid chains), researching and developing new medications based on these, thereby creating innovative compounds through engineering and designing bioprocesses/chemical synthesis of new proteins and fusion of proteins (chimeras/fusion proteins) with new sequences/structures/enzyme linkages, amino acids, genes, and/or chemical bonds of separate proteins, aiming for high efficacy and safety for selected therapeutic targets.
We currently have 20 proprietary Research and Development projects underway, at various stages. Below, we present a small selection across different therapeutic targets.:.
BIOPROCESS DEVELOPMENT STAGE
DESIN-B-BR-P-0005 - FUSION PROTEIN (CHIMERA) - WITH ANTIVIRAL ACTIVITY AGAINST ARBOVIRUSES (Dengue, Zika, West Nile, Usutu, Saint Louis, Yellow Fever).
Additional information
BIOPROCESS DEVELOPMENT STAGE
DESIN-B-BR-P-0007 - FUSION PROTEIN (CHIMERA) - WITH ANTIVIRAL ACTIVITY AGAINST SARS COVID
Additional information
IN SILICO RESEARCH AND DESIGN STAGE
DESIN-B-UK-P-0008 - FUSION PROTEIN (CHIMERA) - OPHTHALMOLOGY - WITH ACTIVITY IN PLACENTAL GROWTH FACTORS AND VEGF
Additional information
IN SILICO RESEARCH AND DESIGN STAGE
DESIN-B-BR-P-0008 - FUSION PROTEIN (CHIMERA) - WITH ANTIVIRAL ACTIVITY AGAINST INFLUENZA
Additional information
IN SILICO RESEARCH AND DESIGN STAGE
DESIN-B-BR-P-00010 - FUSION PROTEIN (CHIMERA) - ANTIFUNGAL - IMMUNOMODULATOR / PROTEASE INHIBITION
Additional information
IN SILICO RESEARCH AND DESIGN STAGE
DESIN-B-UK-P-0008 - FUSION PROTEIN (CHIMERA) - GEOGRAPHIC ATROPHY (C3 & C5 INHIBITION)
Additional information